A pilot trial of immunotherapy with WT1 peptide vaccine for pediatric patients with bone or soft tissue sarcoma following conventional chemotherapy.

A pilot trial of immunotherapy with WT1 peptide vaccine for pediatric patients with bone or soft tissue sarcoma following conventional chemotherapy. - A pilot trial of immunotherapy with WT1 peptide vaccine for pediatric patients with bone or soft tissue sarcoma following conventional chemotherapy.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005312

Enrollment

Registered

2011-03-25

Start date

2010-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteosarcoma Soft tissue sarcoma neuroblastoma Pediatric bone, soft tissue sarcoma at high risk of recurrence.

Interventions

See Japanese protocol or ask directly to us.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: See Japanese protocol or ask directly to us.

Exclusion criteria

Exclusion criteria: See Japanese protocol or ask directly to us.

Design outcomes

Primary

Measure	Time frame
Time to progression from the end of conventional chemotherapy.	—

Countries

Japan

Contacts

Public ContactYoshiko Hashii

Osaka univ Pediatrics

areken@ped.med.osaka-us.jp06-6879-3932

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026